Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,118.95 -29.89 (-2.60%)
Streaming Delayed Price Updated: 11:22 AM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Eli Lilly Could Swing Over $76 Billion In Value After Earnings ↗
Earnings season is approaching, and Benzinga Pro has a list of top stocks to watch. Gilead Sciences and Uber Technologies are expected to have significant market moves based on their upcoming earnings... 
Via Benzinga
News headline image
Which Is the Better State Street Healthcare ETF: The Broad XLV or the Biotech XBI? ↗
XBI surged 76% in one year but carries triple the expense ratio and far steeper downside risk. Which fund matches your risk appetite? 
Via The Motley Fool
Topics ETFs
News headline image
Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? ↗
Abbott trades at half Lilly's valuation multiple, but Lilly's 45% revenue surge and 32% net margin raise the stakes for growth-focused investors. 
Via The Motley Fool
Eli Lilly (NYSE:LLY): A Quality Dividend Stock with Sustainable Growth and Strong Fundamentals ↗
Via Chartmill
News headline image
XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy? ↗
IBBQ posted the stronger return over the past year, but has also experienced much higher historical volatility than XLV. 
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
Prediction: Eli Lilly Will Be Worth $2 Trillion by 2031 ↗
And it will likely be the first company in the sector to get there. 
Via The Motley Fool
News headline image
XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist? ↗
PBE surged 41% in one year but endured a 35% drawdown, while XLV's diversified approach delivered steadier gains with half the volatility. 
Via The Motley Fool
Topics ETFs
News headline image
Healthcare Stocks Are Having a Good Year. Should You Buy a Fidelity or iShares ETF to Profit? ↗
FHLC holds 334 positions versus IYH's 100, yet both delivered similar five-year returns despite their structural differences. 
Via The Motley Fool
Topics ETFs
News headline image
Novo Nordisk Shares Plunge After a Key Trial Fails. Should Investors Buy the Dip? ↗
With the stock near a 5-year low, is it worth a look? 
Via The Motley Fool
News headline image
Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore. ↗
The global market for obesity drugs is soaring, yet Lilly has a dominant market share. 
Via The Motley Fool
News headline image
XLV vs. IHE: Which Healthcare ETF Is the Better Buy? ↗
IHE's pharma-focused portfolio delivered higher returns over the past year, while XLV offers a broader healthcare focus with a much lower expense ratio. 
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels ↗
Wegovy and Zepbound makers Novo Nordisk and Eli Lilly faced pressure. 
Via Investor's Business Daily
News headline image
Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or Invesco's Equal-Weight RSPH? ↗
FHLC's 0.08% expense ratio and market-cap approach delivered stronger returns, while RSPH's equal-weight strategy offers lower volatility and broader diversification across 60 holdings. 
Via The Motley Fool
Topics ETFs
News headline image
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target ↗
There are other reasons to pay attention to Viking Therapeutics. 
Via The Motley Fool
News headline image
VHT vs. PBE: Which Health Care ETF Is the Better Buy? ↗
PBE delivered the better return over the past year, but has experienced greater historical volatility. VHT's more diversified portfolio and rock-bottom fees offer investors a steadier, lower-cost... 
Via The Motley Fool
Topics ETFs
News headline image
Jim Cramer: Eli Lilly Is A 'Good Company,' But Doesn't 'Really Care For' This Quantum Stock ↗
CNBC's Mad Money Lightning Round: Cramer says Astera Labs (ALAB) is a buy, but doesn't care for Rigetti Computing (RGTI). Eli Lilly (LLY) is a classic own, don't trade. MakeMyTrip (MMYT) coverage... 
Via Benzinga
News headline image
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now ↗
But is that performance sustainable? 
Via The Motley Fool
News headline image
3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold ↗
They may profit from the rapidly growing GLP-1 market in very different ways. 
Via The Motley Fool
News headline image
State Street vs. First Trust: Is a Broad Healthcare or Biotech Focus Better for Your Portfolio? ↗
FBT delivered 48.5% returns over one year but carries a 0.55% expense ratio and experiences greater volatility. XLV offers lower costs, with an 0.08% expense ratio, as well as broader diversification... 
Via The Motley Fool
Topics ETFs
News headline image
Forget Weight Loss Drugs: Here's Another Reason to Buy Eli Lilly Stock ↗
Lilly's pipeline is on track to pick up a handful of interesting new programs. 
Via The Motley Fool
News headline image
Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients ↗
Will this pharma company become a new leader in the weight loss market? 
Via The Motley Fool
News headline image
Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth ↗
Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a once-wide gap. 
Via The Motley Fool
News headline image
Only 2 "Magnificent Seven" Stocks Are Beating the Market This Year. What's Going On? ↗
The market has hit new records this year, but it isn't the "Magnificent Seven" stocks that are leading the way. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet. ↗
Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market. 
Via The Motley Fool
Topics ETFs Government
News headline image
4 Stocks That Can 4x Your Money in 4 Years ↗
Quadrupling your money in four years is an incredible rate of return. 
Via The Motley Fool
News headline image
Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs ↗
The company isn't resting on its laurels. 
Via The Motley Fool
News headline image
VUG vs. VTI: Which Vanguard ETF Is the Better Buy for Growth Stocks? ↗
Can growth stocks maintain their momentum, or is it time to diversify? 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
Where Will Novo Nordisk Stock Be in 3 Years? ↗
Trailing a powerful competitor, Novo Nordisk could stay firmly in second place for a good while. 
Via The Motley Fool
News headline image
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees ↗
VHT's diversified portfolio of 411 holdings delivered $1,278 from a $1,000 investment over five years, while its lower expense ratio and higher dividend yield appeal to income investors. 
Via The Motley Fool
Topics ETFs
News headline image
SCHD vs. VIG: Which Dividend ETF Could Build More Wealth Over 20 Years? ↗
The Schwab U.S. Dividend Equity ETF has the superior selection strategy, while the Vanguard Dividend Appreciation ETF has a bigger growth and tech tilt. 
Via The Motley Fool
Topics ETFs Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.